In certain types of gastrointestinal cell, mutations in the protein KIT give rise to gastrointestinal stromal tumours. Why are other cell types that express KIT not affected? The answer lies with a second protein. See Letter p.849
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chi, P. et al. Nature 467, 849–853 (2010).
Kleinbaum, E. P. et al. Int. J. Cancer 122, 711–718 (2008).
Bardsley, M. R. et al. Gastroenterology 139, 942–952 (2010).
Sommer, G. et al. Proc. Natl Acad. Sci. USA 100, 6706–6711 (2003).
Honda, H. et al. Blood 85, 2853–2861 (1995).
Fodde, R., Smits, R., Hofland, N., Kielman, M. & Meera Khan, P. Cytogenet. Cell Genet. 86, 105–111 (1999).
Seth, A. & Watson, D. K. Eur. J. Cancer 41, 2462–2478 (2005).
Clark, J. P. & Cooper, C. S. Nature Rev. Urol. 6, 429–439 (2009).
Ordóñez, J. L., Osuna, D., Herrero, D., de Álava, E. & Madoz-Gúrpide, J. Cancer Res. 69, 7140–7150 (2009).
Jané-Valbuena, J. et al. Cancer Res. 70, 2075–2084 (2010).
Le Cesne, A. et al. Lancet Oncol. 11, 942–949 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
* M.C.H.: Research funding from Novartis/Consultant and equity interest in MolecularMD. * C.L.C.: Novartis: consulting fees, honoraria, research contract/Pfizer: consulting fees, honoraria/Asuragen: consulting fee/MolecularMD: consulting fees, research contract/Synta: research contract/SuperGen: research contract
Rights and permissions
About this article
Cite this article
Heinrich, M., Corless, C. Oncogenes in context. Nature 467, 796–797 (2010). https://doi.org/10.1038/467796a
Published:
Issue Date:
DOI: https://doi.org/10.1038/467796a
